Cara Therapeutics Analyst Ratings
Cara Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | -18.03% | Piper Sandler | $12 → $1 | Downgrades | Overweight → Neutral |
| 10/19/2023 | 473.77% | HC Wainwright & Co. | $15 → $7 | Maintains | Buy |
| 08/08/2023 | 883.61% | Piper Sandler | $13 → $12 | Maintains | Overweight |
| 08/08/2023 | 1703.28% | Needham | → $22 | Reiterates | Buy → Buy |
| 06/27/2023 | 2195.08% | Stifel | → $28 | Reiterates | Buy → Buy |
| 06/27/2023 | 1375.41% | Jefferies | → $18 | Reiterates | Buy → Buy |
| 05/16/2023 | 1129.51% | HC Wainwright & Co. | $20 → $15 | Maintains | Buy |
| 05/16/2023 | 227.87% | B of A Securities | $6 → $4 | Maintains | Underperform |
| 05/16/2023 | 1703.28% | Needham | → $22 | Reiterates | → Buy |
| 04/18/2023 | 1703.28% | Needham | → $22 | Reiterates | → Action List Buy |
| 04/04/2023 | 1703.28% | Needham | → $22 | Reiterates | → Buy |
| 03/08/2023 | 391.8% | B of A Securities | $13 → $6 | Downgrades | Neutral → Underperform |
| 03/07/2023 | 1211.48% | JP Morgan | $19 → $16 | Maintains | Overweight |
| 03/07/2023 | 1949.18% | Canaccord Genuity | $29 → $25 | Maintains | Buy |
| 03/07/2023 | 1703.28% | Needham | $26 → $22 | Maintains | Buy |
| 03/07/2023 | 965.57% | Piper Sandler | $25 → $13 | Maintains | Overweight |
| 03/07/2023 | 1539.34% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 02/17/2023 | 2031.15% | Needham | → $26 | Reiterates | → Buy |
| 02/14/2023 | 1949.18% | HC Wainwright & Co. | $30 → $25 | Maintains | Buy |
| 03/14/2022 | 2277.05% | Canaccord Genuity | $33 → $29 | Maintains | Buy |
| 03/14/2022 | 2359.02% | HC Wainwright & Co. | $35 → $30 | Maintains | Buy |
| 03/08/2022 | 1539.34% | JP Morgan | $17 → $20 | Upgrades | Neutral → Overweight |
| 08/24/2021 | 2768.85% | HC Wainwright & Co. | $33 → $35 | Maintains | Buy |
| 08/03/2021 | 1211.48% | JP Morgan | → $16 | Initiates Coverage On | → Neutral |
| 04/29/2021 | 2031.15% | Needham | $35 → $26 | Maintains | Buy |
| 05/19/2020 | 3178.69% | Cantor Fitzgerald | $34 → $40 | Reiterates | → Overweight |
| 04/22/2020 | 71211.48% | Wedbush | $34 → $870 | Maintains | Outperform |
| 04/22/2020 | 2686.89% | Cantor Fitzgerald | $26 → $34 | Reiterates | → Overweight |
| 07/30/2019 | 3096.72% | Piper Sandler | $35 → $39 | Maintains | Overweight |
| 05/29/2019 | 2195.08% | HC Wainwright & Co. | $26 → $28 | Maintains | Buy |
| 05/29/2019 | 2768.85% | Needham | $28 → $35 | Maintains | Buy |
| 02/06/2019 | 1703.28% | Jefferies | → $22 | Assumes | → Buy |
| 01/15/2019 | 1457.38% | B of A Securities | → $19 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | -18.03% | 派珀·桑德勒 | 12 美元 → $1 | 降級 | 超重 → 中性 |
| 2023 年 10 月 19 日 | 473.77% | HC Wainwright & Co. | 15 美元 → 7 美元 | 維護 | 買 |
| 08/08/2023 | 883.61% | 派珀·桑德勒 | 13 美元 → 12 美元 | 維護 | 超重 |
| 08/08/2023 | 1703.28% | 尼德姆 | → 22 美元 | 重申 | 購買 → 購買 |
| 06/27/2023 | 2195.08% | Stifel | → 28 美元 | 重申 | 購買 → 購買 |
| 06/27/2023 | 1375.41% | 傑富瑞集團 | → 18 美元 | 重申 | 購買 → 購買 |
| 05/16/2023 | 1129.51% | HC Wainwright & Co. | 20 美元 → 15 美元 | 維護 | 買 |
| 05/16/2023 | 227.87% | B of A 類證券 | 6 美元 → 4 美元 | 維護 | 表現不佳 |
| 05/16/2023 | 1703.28% | 尼德姆 | → 22 美元 | 重申 | → 購買 |
| 04/18/2023 | 1703.28% | 尼德姆 | → 22 美元 | 重申 | → 動作清單購買 |
| 04/04/2023 | 1703.28% | 尼德姆 | → 22 美元 | 重申 | → 購買 |
| 03/08/2023 | 391.8% | B of A 類證券 | 13 美元 → 6 美元 | 降級 | 中性 → 跑贏大盤 |
| 03/07/2023 | 1211.48% | 摩根大通 | 19 美元 → 16 美元 | 維護 | 超重 |
| 03/07/2023 | 1949.18% | Canaccord Genu | 29 美元 → 25 美元 | 維護 | 買 |
| 03/07/2023 | 1703.28% | 尼德姆 | 26 美元 → 22 美元 | 維護 | 買 |
| 03/07/2023 | 965.57% | 派珀·桑德勒 | 25 美元 → 13 美元 | 維護 | 超重 |
| 03/07/2023 | 1539.34% | HC Wainwright & Co. | 25 美元 → 20 美元 | 維護 | 買 |
| 02/17/2023 | 2031.15% | 尼德姆 | → 26 美元 | 重申 | → 購買 |
| 02/14/2023 | 1949.18% | HC Wainwright & Co. | 30 美元 → 25 美元 | 維護 | 買 |
| 03/14/2022 | 2277.05% | Canaccord Genu | 33 美元 → 29 美元 | 維護 | 買 |
| 03/14/2022 | 2359.02% | HC Wainwright & Co. | 35 美元 → 30 美元 | 維護 | 買 |
| 03/08/2022 | 1539.34% | 摩根大通 | 17 美元 → 20 美元 | 升級 | 中性 → 超重 |
| 08/24/2021 | 2768.85% | HC Wainwright & Co. | 33 美元 → 35 美元 | 維護 | 買 |
| 08/03/2021 | 1211.48% | 摩根大通 | → 16 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 04/29/2021 | 2031.15% | 尼德姆 | 35 美元 → 26 美元 | 維護 | 買 |
| 2020 年 5 月 19 日 | 3178.69% | 坎託·菲茨傑拉德 | 34 美元 → 40 美元 | 重申 | → 超重 |
| 2020 年 4 月 22 日 | 71211.48% | Wedbush | 34 美元 → 870 美元 | 維護 | 跑贏大盤 |
| 2020 年 4 月 22 日 | 2686.89% | 坎託·菲茨傑拉德 | 26 美元 → 34 美元 | 重申 | → 超重 |
| 2019 年 7 月 30 日 | 3096.72% | 派珀·桑德勒 | 35 美元 → 39 美元 | 維護 | 超重 |
| 05/29/2019 | 2195.08% | HC Wainwright & Co. | 26 美元 → 28 美元 | 維護 | 買 |
| 05/29/2019 | 2768.85% | 尼德姆 | 28 美元 → 35 美元 | 維護 | 買 |
| 02/06/2019 | 1703.28% | 傑富瑞集團 | → 22 美元 | 假設 | → 購買 |
| 01/15/2019 | 1457.38% | B of A 類證券 | → 19 美元 | 啓動覆蓋範圍開啓 | → 中立 |
What is the target price for Cara Therapeutics (CARA)?
Cara Therapeutics（CARA）的目標價格是多少？
The latest price target for Cara Therapeutics (NASDAQ: CARA) was reported by Piper Sandler on November 14, 2023. The analyst firm set a price target for $1.00 expecting CARA to fall to within 12 months (a possible -18.03% downside). 19 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年11月14日公佈了Cara Therapeutics（納斯達克股票代碼：CARA）的最新目標股價。該分析公司將目標股價定爲1.00美元，預計CARA將在12個月內跌至12個月內（可能下跌18.03％）。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Cara Therapeutics (CARA)?
分析師對Cara Therapeutics（CARA）的最新評級是多少？
The latest analyst rating for Cara Therapeutics (NASDAQ: CARA) was provided by Piper Sandler, and Cara Therapeutics downgraded their neutral rating.
派珀·桑德勒對Cara Therapeutics（納斯達克股票代碼：CARA）的最新分析師評級由派珀·桑德勒提供，Cara Therapeutics下調了中性評級。
When is the next analyst rating going to be posted or updated for Cara Therapeutics (CARA)?
Cara Therapeutics（CARA）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cara Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Cara Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Cara Therapeutics的最新評級是在2023年11月14日公佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Cara Therapeutics (CARA) correct?
分析師對 Cara Therapeutics (CARA) 的評級正確嗎？
While ratings are subjective and will change, the latest Cara Therapeutics (CARA) rating was a downgraded with a price target of $12.00 to $1.00. The current price Cara Therapeutics (CARA) is trading at is $1.22, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Cara Therapeutics（CARA）評級已下調，目標股價爲12.00美元至1.00美元。Cara Therapeutics（CARA）目前的交易價格爲1.22美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。